MorphoSys says its pipeline numbers more than 100 human antibody drug candidates for cancer, as well as rheumatoid arthritis, Alzheimer's disease, and other disorders. Three of the company's four clinical-phase drug candidates focus on cancer—MOR208 for B-cell malignancies, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; MOR202 for multiple myeloma and some forms of leukemia and MOR209/ES414, a prostate cancer treatment being developed through a MorphoSys collaboration with Emergent BioSolutions. Earlier this year MorphoSys regained rights to MOR202 from Celgene after the companies "mutually agreed" to terminate a 21-month-old co-development and co-promotion agreement. immatics focuses on developing cancer immunotherapeutics.